Revenue segments as reported by the company.

Service revenue

Product revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Charles River Laboratories

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients’ research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Charles River Labs posts record revenue in Q4 2022

Charles River Laboratories delivered a robust performance in Q4 2022, achieving record revenue and exceeding earnings expectations.
While facing challenges such as NHP supply constraints and regulatory issues, the company showcased operational strength and strategic resilience.
Management's focus on addressing headwinds and exploring growth opportunities positions Charles River Laboratories for future success.
Navigating uncertainties in 2023, the company aims to maintain financial stability and drive growth through strategic initiatives.

Charles River Laboratories reports strong Q1 performance amidst NHP challenges

Charles River Laboratories (CRL) had a strong Q1 performance, exceeding expectations and narrowing 2023 guidance amidst NHP supply constraints impact.
Clients continue to choose Charles River for its expertise and solutions, with segments showing growth potential and disciplined capital deployment.
Challenges include NHP supply issues, margin impact concerns, and predicting demand trends, while opportunities lie in rebounding growth and market positioning.
Overall, Charles River remains focused on navigating challenges, leveraging strengths, and capitalizing on growth opportunities in the biopharmaceutical market.

Charles River Labs reports strong Q2 performance amidst market challenges

Charles River Laboratories (CRL) delivered a strong Q2 performance, facing challenges in the DSA segment but expecting improvements in various business segments. The company is capitalizing on its strengths in client mix and global footprint for NHP work, while addressing challenges such as inflationary pressures and aggressive pricing from competitors.

Charles River Labs surpasses Q3 expectations amidst client caution

Charles River Laboratories delivered a solid performance in Q3, exceeding earnings expectations despite challenges from cautious client spending and margin pressures. Strategic initiatives focusing on innovation, compliance, and cost-saving measures are key strengths. Opportunities in successful client support, advanced technology investments, and supply chain enhancements position the company for future growth.

Charles River Labs reports solid 2023 growth, eyes stable 2024

Charles River Laboratories reported solid revenue growth in 2023, with a focus on operational efficiency and revenue enhancement strategies.
While facing challenges like revenue decline in Q4 and fluctuating cancellation rates, the company is optimistic about stable client spending and growth opportunities in 2024.
With a strong performance in the pharma business and strategic acquisitions, Charles River Laboratories is poised for margin improvement and revenue expansion in the coming year.
The company's confidence in pricing strategy, supply stability, and potential for share gains highlight its competitive position and growth prospects.

Charles River Labs reports mixed Q1 results, eyes sequential improvements

Charles River Laboratories navigated mixed Q1 results with strong performances in Manufacturing and RMS segments.
Challenges include slow recovery in Discovery business and potential staff availability constraints in Safety Assessment.
Opportunities lie in sequential improvements in DSA, increased bookings, and careful management of demand environment.

Charles River Labs Q2 revenue declines, focuses on cost efficiency

Charles River Laboratories faces challenges from softening demand trends impacting revenue but is taking actions to streamline costs and optimize operations. Despite revenue decline, the company's manufacturing segment shows growth potential. Opportunities exist in cost savings initiatives and focusing on CDMO business growth.

Charles River Labs beats Q3 expectations, eyes biopharma opportunities

Charles River Laboratories (CRL) delivered strong financial performance in Q3, focusing on cost management and strategic growth initiatives. Despite challenges in the biopharmaceutical sector, opportunities exist in CDMO and Biologics Testing businesses.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.3%, and acquisitions contributed 1.5% to consolidated first-quarter revenue. A small divestiture of a Safety Assessment site reduced reported revenue by 0.2%.

Charles River Laboratories Announces First-Quarter 2024 Results

Corporacion America Airports

Endava plc - ADR

Intel

Keysight

Texas Instruments

VeriSign

It's been a tremendous year for growth stocks. New technologies and increasing consumer adoption in fields such a semiconductors, electric vehicles, and generative AI have led to tremendous gains for growth stocks.

The 7 Best Growth Stocks to Buy in May 2024

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior e.

Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP

ICON

Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?

ICLR vs. CRL: Which Stock Is the Better Value Option?

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.

Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

Here's Why You Should Retain Charles River (CRL) Stock Now

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives to reduce animal testing.

Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing

Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?

ICLR or CRL: Which Is the Better Value Stock Right Now?

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible throug.

Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call

Charles River (CRL) is set to perform plasmid production for Ship of Theseus.

Charles River (CRL) Forges Collaboration With Ship of Theseus

WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex launch Patholytix Foresight, an AI-powered decision support tool for toxicologic pathology.

Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia's gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure. Ciliopathies are diseases caus.

Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus will leverage Charles River's premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate. Sh.

Charles River to Perform Plasmid Production for Ship of Theseus

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting. Charles River will present technology-driven capabilities and highlight the latest advancements in immuno-oncology, in vitro assays, and more. The meeting is taking place from April 5-10, 2024, at the San Diego Convention Center in San Diego, California. Ch.

Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023 report demonstrates Charles River's priorities and commitments across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet. “The work we do at Char.

Charles River Laboratories Publishes 2023 Corporate Citizenship Report

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore's (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement. NUS Medicine will utilize Charles River's market leading contract development and manufacturing organiz.

Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Charles River (CRL) Extends Gene Therapy Offering With New Pact

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene t.

Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will present at the Charles River Cell & Gene Therapy Summit at 2:00 p.m. PT, Tuesday, March 19, 2024, in South San Francisco, Calif.

Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories To Present At Barclays Global Healthcare Conference.

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Johnson & Johnson

Medtronic

Stock markets are reaching new highs and exuberance is in the air. For value investors, this might seem like a perplexing time.

News for Charles River Laboratories Stock (CRL)